Connecticut Oncology Association


The Connecticut Oncology Association represents more than 100 physicians and other health care professionals who care for cancer patients. The Society is a non-profit corporation devoted to the improvement of hematologic and oncologic care of patients.

Membership in the Society is open to physicians, allied health professionals, and institutions with a demonstrated interest and involvement in the care of patients with hematologic and oncologic disorders. It is also open to residents and fellows who are actively enrolled in a full-time residency program in hematology or oncology in Connecticut or who are in an appropriate fellowship program. Corporate entities involved in the care and treatment of cancer patients may also become members.

The Connecticut Oncology Association is grateful to our Corporate Sponsors, whose donations help us fulfill our mission.

Corporate Sponsor Virtual Broadcast: 

Current Policy/Advocacy Concerns for CT patients

Anthem Oncology Dose Reduction Program for Medicare Advantage Patients

The CT Policy, effective as of July 1, 2021

The NOSN Policy on Dose Reduction Programs, and this Anthem Program

Stay up to date on the latest cancer related bills in the Connecticut Legislature


2024 Legislative Session

Click on Bill for language and CtOA Written Testimony

SB 08 - An Act concerning Drug Affordability - PDAB, Drug Importation, Upper Drug Payment Limits

CtOA Written and oral Testimony 03/05/2024

Raised HB 05319 An Act Concerning Private Equity firms Acquiring or Holding an Ownership Interest in Health care Facilities

CtOA Written and Oral Testimony  03/06/2024

Raised HB 307 An Act concerning Medicaid Coverage of Biomarker Testing

CtOA Written and Oral Testimony 03/12/2024

2021 SB 1003 Signed into Law for Jan 2022 - CoPay Accumulator Programs Not allowed in CT  

Senate Bill No. 1003

Public Act No. 21-14





COVID-19 2020 Update:  Our meeting schedule, which usually begins in March, has been disrupted by the pandemic restrictions.  We will be scheduling panel discussions and webinars over 2022, and look forward to seeing you all in person as soon as possible!  Stay safe and take care of each other and your families.  Please visit our Corporate Partners page for current contacts information from our Corporate Partners.

Upcoming Meetings & Events

Go to Events page for more information

News From Charter Oak Corporate Sponsors:

BMS   U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) 3/14/2024

Genentech FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer  10/15/2021

BMS Celgene  COVID-19 Our Response and Path Forward - 05/13/2020

Exelixis announces first 100 patients enrolled in Phase 3 02/25/2020

Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain 06/29/2020

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation 06/24/2020

FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA® (pembrolizumab), Regardless of Tumor Type


FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma


U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer


Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib (TAK-788) for the Treatment of NSCLC Patients with EGFR Exon 20 Insertion Mutations  04/27/2020

09/30/2019 AstraZeneca - Tagrisso is the only 1st-line treatment for EGFR-mutated non-small cell lung cancer to deliver a median overall survival of more than three years Press Release

08/16/2-19 Celgene -

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis  Press Release

09/29/2019 Merck - Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)  Press Release

10/01/2018 Takeda - Positive Results Press Release 

09/25/2018 AstraZeneca - Overall Survival Press Release 

09/24/2018 Astellas - Postive CHMP Opinion Press Release

08/06/2018 Teva - Updated Indication Press Release

06/28/2018 Array BioPharma - New Indication - BRAFTOVI™ (encorafenib) Press Release 

03/26/2018 Seattle Genetics - FDA Breakthrough Therapy Designation Press Release

N02-11-2016  Merck - New Indication  PressRelease.pdf

12-15-2015 - Genentech - ALECENSA® (alectinib)  ALECENSAPracticeManagerDay1Letters_ATP.pdf

Cancer News

Payment for Event - $50 for non-member or additional Corporate Partner (Must Register separately)

Connecticut Oncology Association (CtOA)

c/o Dawn Holcombe

33 Woodmar Circle
South Windsor, CT  06074
(860) 305-4510

Website design by Sister Webs Design Studio, where 5% of profits are donated to women's cancer funds

Powered by Wild Apricot Membership Software